Complete response to ipilimumab and nivolumab therapy in a patient with extensive extrapulmonary high-grade small cell carcinoma of the pancreas and HIV infection.

ABSTRACT:

Background

Immune checkpoint inhibitors (CPIs) have shown promising results in many solid tumors. There are limited data on the safety and efficacy of these drugs in HIV infected patients as they have traditionally been excluded from CPIs clinical trials.

Case presentation

We present a case of an HIV-positive patient with extensive extrapulmonary high-grade small cell carcinoma who was treated with dual CPIs (nivolumab and ipilimumab) with a complete response to therapy and with a manageable safety profile. We performed a comprehensive literature review identifying 62 total HIV positive cases treated with CPIs showing this to be a potentially safe option in HIV-positive patients.

Conclusion

HIV infection is not an absolute contraindication to CPI therapy. Our case and

SUBMITTER: Husnain M 

PROVIDER: S-EPMC6036694 | biostudies-literature | 2018 Jul

REPOSITORIES: biostudies-literature